Literature DB >> 21339183

Different expression patterns of Ngb and EPOR in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of Neuro-EPO for ischemic insults to the gerbil brain.

Yan Gao1, Yuneidis Mengana, Yamila Rodríguez Cruz, Adriana Muñoz, Iliana Sosa Testé, Jorge Daniel García, Yonghong Wu, Julio César García Rodríguez, Chenggang Zhang.   

Abstract

The purpose of this study was to evaluate the neuroprotective effects of intranasally delivered recombinant human neuronal erythropoietin (Neuro-EPO) on brain injury induced by unilateral permanent ischemia in the Mongolian gerbil. Expression of EPO receptor (EPOR) and neuroglobin (Ngb) over 5 weeks after intranasal treatment with Neuro-EPO was determined using immunohistochemistry. Mortality of Neuro-EPO-treated gerbils decreased after surgery, and the sensory and motor function was significantly improved. Histopathological mapping showed that Neuro-EPO significantly reduced delayed neuronal death in the brain. Expression of Ngb was upregulated in the cerebral cortex at most time points (expect for 10 min and 48 hr) and in the hippocampus at 10 min and from 48 hr to 5 weeks, whereas EPOR was almost downregulated or unchanged in the brain (expect for 48 hr). The 10 min and 48 hr seemed to be two time points for the brain to switch the expression of both Ngb and EPOR to early and late recovery phase, respectively. In addition, there were two phases, 10 min to 1 hr and 24 hr to 72 hr, respectively, closing to the "golden hour" of about 60 min and the "silver day" of 1 to 3 days, for the brain to recover from stroke onset with intranasal Neuro-EPO treatment. Therefore, the results suggest that the intranasal administration of Neuro-EPO is effective in the treatment of acute brain ischemia. The different expression patterns of Ngb and EPOR is probably due to ischemic tolerance in the cerebral cortex and ischemic sensitivity in the hippocampus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21339183      PMCID: PMC3201137          DOI: 10.1369/0022155410390323

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  41 in total

1.  In vivo evidence that erythropoietin has a neuroprotective effect during subarachnoid hemorrhage.

Authors:  M Buemi; G Grasso; F Corica; G Calapai; F M Salpietro; T Casuscelli; A Sfacteria; C Aloisi; C Alafaci; A Sturiale; N Frisina; F Tomasello
Journal:  Eur J Pharmacol       Date:  2000-03-24       Impact factor: 4.432

2.  On the future of reanimatology.

Authors:  P Safar
Journal:  Acad Emerg Med       Date:  2000-01       Impact factor: 3.451

3.  A vertebrate globin expressed in the brain.

Authors:  T Burmester; B Weich; S Reinhardt; T Hankeln
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

4.  Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin.

Authors:  C Wiessner; P R Allegrini; D Ekatodramis; U R Jewell; T Stallmach; M Gassmann
Journal:  J Cereb Blood Flow Metab       Date:  2001-07       Impact factor: 6.200

5.  Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain.

Authors:  A L Sirén; F Knerlich; W Poser; C H Gleiter; W Brück; H Ehrenreich
Journal:  Acta Neuropathol       Date:  2001-03       Impact factor: 17.088

6.  The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset.

Authors:  Jeffrey L Saver; Eric E Smith; Gregg C Fonarow; Mathew J Reeves; Xin Zhao; Daiwai M Olson; Lee H Schwamm
Journal:  Stroke       Date:  2010-06-03       Impact factor: 7.914

7.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress.

Authors:  A L Sirén; M Fratelli; M Brines; C Goemans; S Casagrande; P Lewczuk; S Keenan; C Gleiter; C Pasquali; A Capobianco; T Mennini; R Heumann; A Cerami; H Ehrenreich; P Ghezzi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

8.  The golden hour and the silver day: detection and correction of occult hypoperfusion within 24 hours improves outcome from major trauma.

Authors:  O Blow; L Magliore; J A Claridge; K Butler; J S Young
Journal:  J Trauma       Date:  1999-11

9.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.

Authors:  M L Brines; P Ghezzi; S Keenan; D Agnello; N C de Lanerolle; C Cerami; L M Itri; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

10.  Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS.

Authors:  Sandra R Alcalá-Barraza; Michael S Lee; Leah R Hanson; Abby A McDonald; William H Frey; Linda K McLoon
Journal:  J Drug Target       Date:  2010-04       Impact factor: 5.121

View more
  8 in total

1.  Intranasal Erythropoietin Protects CA1 Hippocampal Cells, Modulated by Specific Time Pattern Molecular Changes After Ischemic Damage in Rats.

Authors:  R J Macias-Velez; L Fukushima-Díaz de León; C Beas-Zárate; M C Rivera-Cervantes
Journal:  J Mol Neurosci       Date:  2019-05-03       Impact factor: 3.444

2.  Interactions between vascular endothelial growth factor and neuroglobin.

Authors:  Kunlin Jin; Xiao Mao; Lin Xie; David A Greenberg
Journal:  Neurosci Lett       Date:  2012-05-11       Impact factor: 3.046

3.  The role of neuroglobin in the neuroprotection of limb ischemic preconditioning in rats.

Authors:  Shu-Qin Li; Wen-Bin Li; Min Zhang; Yu-Zhou Wu; Yu-Yan Hu
Journal:  Mol Neurobiol       Date:  2012-11-21       Impact factor: 5.590

4.  Dose effect evaluation and therapeutic window of the neuro-EPO nasal application for the treatment of the focal ischemia model in the Mongolian gerbil.

Authors:  Iliana Sosa Teste; Yuneidys Mengana Tamos; Yamila Rodríguez Cruz; Adriana Muñoz Cernada; Janette Cruz Rodríguez; Nelvis Subirós Martínez; Rosa Maria Coro Antich; Alina González-Quevedo; Julio Cesar García Rodríguez
Journal:  ScientificWorldJournal       Date:  2012-05-22

Review 5.  Neuroglobin in Retinal Neurodegeneration: A Potential Target in Therapeutic Approaches.

Authors:  Virginia Solar Fernandez; Maria Marino; Marco Fiocchetti
Journal:  Cells       Date:  2021-11-17       Impact factor: 6.600

6.  Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study.

Authors:  Orestes Santos-Morales; Alina Díaz-Machado; Daise Jiménez-Rodríguez; Yaisel Pomares-Iturralde; Tatiana Festary-Casanovas; Carlos A González-Delgado; Sonia Pérez-Rodríguez; Eulalia Alfonso-Muñoz; Carmen Viada-González; Patricia Piedra-Sierra; Idrian García-García; Daniel Amaro-González; Julio César García-Rodríguez; Iliana Sosa-Testé; Alicia Lagarto-Parra; Laura Barrero-Viera; Marlene David-Baldo; Maura Tamayo-Rodríguez; Ivonne Rivero-Vázquez; Gricel González-Gamiz; Alis Martín-Trujillo; Yasmila Rodríguez-Fernández; Ana Alfa Ledo-de la Luz; Maylén Álvarez-Delgado; Ivón Howland-Álvarez; Yolanda Cruz-Gómez
Journal:  BMC Neurol       Date:  2017-07-04       Impact factor: 2.474

Review 7.  Lessons from the post-genomic era: Globin diversity beyond oxygen binding and transport.

Authors:  Anna Keppner; Darko Maric; Miguel Correia; Teng Wei Koay; Ilaria M C Orlando; Serge N Vinogradov; David Hoogewijs
Journal:  Redox Biol       Date:  2020-08-14       Impact factor: 11.799

8.  Unannotated single nucleotide polymorphisms in the TATA box of erythropoiesis genes show in vitro positive involvements in cognitive and mental disorders.

Authors:  Mikhail Ponomarenko; Ekaterina Sharypova; Irina Drachkova; Irina Chadaeva; Olga Arkova; Olga Podkolodnaya; Petr Ponomarenko; Nikolay Kolchanov; Ludmila Savinkova
Journal:  BMC Med Genet       Date:  2020-10-22       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.